Company intelligence / Profile preview
Taiyun Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Taiyun Pharmaceutical is a clinical-stage biopharmaceutical company based in China, dedicated to the discovery and development of innovative therapies for oncology and autoimmune diseases. The company focuses on high-potential targets such as EGFR and VEGFR, utilizing both small molecule and monoclonal antibody modalities. Taiyun's pipeline includes several candidates in various stages of clinical development, aimed at addressing significant unmet medical needs in the treatment of solid tumors and inflammatory conditions. By leveraging its internal R&D capabilities and strategic collaborations, Taiyun Pharmaceutical strives to deliver effective and accessible medicines to patients globally.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Taiyun Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taiyun Pharmaceutical.